AEON Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
AEON$0.18-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
** (in thousands) (Unaudited)**
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Six Months Ended | ||||||
| · · June 30, | ||||||
| · · 2026 · · 2025 | ||||||
| Cash flows from operating activities: · · · · · | ||||||
| Net (loss) income | | $(12,948) | | $2,453 | ||
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | | | | | ||
| Depreciation | | 39 | | 39 | ||
| Stock-based compensation expense | | | 3,591 | | 3,311 | |
| Loss on issuance of warrants | | — | | 75,644 | ||
| Loss on extinguishment of debt | | | 76 | | — | |
| Change in fair value of convertible notes | | | 8,940 | | 3,485 | |
| Change in fair value of warrants | | | (9,597) | | (86,187) | |
| Loss on derivative liability | | | 1,743 | | | — |
| Change in fair value of contingent consideration | | | (15) | | | (3,472) |
| Changes in operating assets and liabilities: | | | | | | |
| Prepaid expenses and other current assets | | (169) | | (245) | ||
| Accounts payable | | 1,755 | | (2,003) | ||
| Accrued expenses and other liabilities | | 159 | | (3,018) | ||
| Other assets and liabilities | | 92 | | (7) | ||
| Net cash used in operating activities | | (6,334) | | (10,000) | ||
| Cash flows from investing activities: | | | | | ||
| Purchases of property and equipment | | — | | (4) | ||
| Net cash used in investing activities | | — | | (4) | ||
| Cash flows from financing activities: | | | | | ||
| Proceeds from PIPE financing | | | 4,208 | | | — |
| Proceeds from issuance of at-the-market shares, net | | | 2,551 | | | 84 |
| Proceeds from issuance of public offering shares, net | | | — | | | 18,346 |
| Net cash provided by financing activities | | 6,759 | | 18,430 | ||
| Net increase in cash | | 425 | | 8,426 | ||
| Cash and cash equivalents at beginning of period | | 3,006 | | 13 | ||
| Cash and cash equivalents at end of period | | $3,431 | | $8,439 | ||
| Supplemental disclosure of cash flow information: | | | | | ||
| Non-cash financing activities: | | | | | ||
| Settlement of convertible notes with common shares | | $31,489 | | $— | ||
| Reclassification of derivative liability to equity and warrant liabilities in connection with PIPE financing | | | 16,622 | | | — |
| Modification of cash-settled restricted stock units | | | 1,952 | | | — |
| Cashless warrant exercises | | $— | | $6,864 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.